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ABSTRACT
Background. This study’s goal was to provide dose–response data for a dopamine
agonist in the baboon using standard methods (replicate measurements at each dose,
across a range of doses), as a standard against which to subsequently validate a novel
pharmacological MRI (phMRI) method. Dependent variables were functional MRI
(fMRI) data from brain regions selected a priori, and systemic prolactin release.
Necessary first steps included estimating the magnitude and time course of prolactin
response to anesthesia alone and to various doses of agonist. These first steps (“time
course studies”) were performed with three agonists, and the results were used to
select promising agonists and to guide design details for the single-dose studies
needed to generate dose–response curves.
Methods. We studied 6 male baboons (Papio anubis) under low-dose isoflurane
anesthesia after i.m. ketamine. Time course studies charted the changes in plasma
prolactin levels over time after anesthesia alone or after an intravenous (i.v.)
dose of the dopamine D1-like agonists SKF82958 and SKF38393 or the D2-like
agonist pramipexole. In the single-dose dopamine agonist studies, one dose of
SKF38393 (ranging from 0.0928–9.28 mg/kg, N = 5 animals) or pramipexole
(0.00928–0.2 mg/kg, N = 1) was given i.v. during a 40-min blood oxygen level
dependent (BOLD) fMRI session, to determine BOLD and plasma prolactin
responses to different drug concentrations. BOLD response was quantified as the area
under the time-signal curve for the first 15 min after the start of the drug infusion,
compared to the linearly predicted signal from the baseline data before drug. The
ED50 (estimated dose that produces 50% of the maximal possible response to drug)
for SKF38393 was calculated for the serum prolactin response and for phMRI re-
sponses in hypothalamus, pituitary, striatum and midbrain.
Results. Prolactin rose 2.4- to 12-fold with anesthesia alone, peaking around
50–90 min after ketamine administration and gradually tapering off but still
remaining higher than baseline on isoflurane 3–5 h after ketamine. Baseline
prolactin level increased with age. SKF82958 0.1 mg/kg i.v. produced no noticeable
change in plasma prolactin concentration. SKF38393 produced a substantial increase
in prolactin release that peaked at around 20–30 min and declined to pre-drug levels
in about an hour. Pramipexole quickly reduced prolactin levels below baseline,
reaching a nadir 2–3 h after infusion. SKF38393 produced clear, dose-responsive
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BOLD signal changes, and across the four regions, ED50 was estimated at
2.6–8.1 mg/kg.
Conclusions. In the baboon, the dopamine D1 receptor agonist SKF38393 produces
clear plasma prolactin and phMRI dose–response curves. Variability in age and a
modest sample size limit the precision of the conclusions.
Subjects Neuroscience, Diabetes and Endocrinology, Pharmacology, Radiology and Medical
Imaging
Keywords Prolactin, SKF82958, Pramipexole, SKF38393, Dopamine D1 receptor agonists,
Ketamine, Isoflurane, fMRI, Papio anubis, Pharmacological fMRI
INTRODUCTION
We recently described a new pharmacological MRI (phMRI) method designed to estimate
a dose–response curve in a single imaging session (Black, Koller & Miller, 2013). We
sought to validate that method using specific dopamine receptor agonists in the baboon, a
primate species with a large enough brain to allow using functional MRI (fMRI) methods
commonly used in humans (Black et al., 2009). However, limited data have been available
on dose–response curves for fMRI responses to dopamine agonists in primate brain.
More data are available on the systemic prolactin response to some dopamine agonists.
The goal of the present work was to use a traditional approach to characterize the
dose–response curves for regional fMRI signal and prolactin responses in baboon to at
least one pharmacologically specific dopamine agonist.
Primate phMRI studies, and before that ex vivo and positron emission tomography
studies of regional cerebral metabolism and blood flow, have been reported for levodopa
and several dopamine agonists (Black et al., 2000; Black et al., 2002; Chen et al., 1997;
Herscovitch, 2001; Hershey et al., 2000; Hershey et al., 2003; Perlmutter, Rowe & Lich, 1993;
Trugman &Wooten, 1986; Trugman & James, 1992; Trugman & James, 1993; Zhang et al.,
2000). However, rarely have phMRI dose–response curves been reported for drugs of any
kind in primates (briefly reviewed in Black et al., 2010).
Prolactin is a hormone best known for its ability to promote lactation in response to
the suckling stimulus of hungry young mammals, but it plays a role in many biological
functions (Freeman et al., 2000). Prolactin is produced principally by the anterior pituitary
gland, and also within the central nervous system, the immune system, the uterus and the
mammary gland. Pituitary prolactin secretion is mediated in large part by dopamine
synthesized by the tuberoinfundibular dopaminergic neurons of the arcuate nucleus
through D2 receptors (Freeman et al., 2000; Jaber et al., 1996; Ben-Jonathan & Hnasko,
2001). Dopamine is the principal prolactin inhibiting factor and increasing dopamine
directly by giving dopamine i.v. reduces plasma prolactin concentration (Leblanc et al.,
1976; Norman, Quadri & Spies, 1980; Freeman et al., 2000; Ben-Jonathan &Hnasko, 2001).
D1 receptor activation also increases prolactin levels most likely by inhibiting the D2
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pathway (Curlewis, Clarke & McNeilly, 1993; Colthorpe et al., 1998; Durham et al., 1998;
Freeman et al., 2000).
SKF82958 is a full agonist at dopamine D1-like receptors, though there is some debate
about full vs. partial agonism (Gilmore et al., 1995; Bergman et al., 1996). SKF82958
produces dose-responsive effects on brain activity (Black et al., 2000), but its effects
on prolactin secretion are not well described. Pramipexole is a D3-preferring D2-like
dopamine agonist (Mierau, 1995; Mierau et al., 1995; Piercey, 1998) that produces
regionally specific effects on brain activity (Black et al., 2002) and reduces prolactin
secretion in humans (Schilling, Adamus & Palluk, 1992; Samuels et al., 2006). For both
of these drugs there is strong evidence that they affect regional cerebral blood flow (rCBF)
via changes in neuronal activity and not via direct vascular effects (Black et al., 2000; Black
et al., 2002). In fact, with few exceptions (such as ergot derivatives), synthetic dopamine
agonists generally do not uncouple brain blood flow from brain metabolism, i.e., are not
expected to affect the BOLD signal except through neuronal effects (discussed in Black et
al., 2000; Black et al., 2002).
SKF38393 is a partial D1 agonist that increases prolactin levels and changes regionally
specific brain activity (Engber et al., 1993; Trugman & James, 1992; Morelli et al., 1993).
There is little information on fMRI or rCBF effects of SKF38393 (Dixon et al., 2001),
but it does affect neuronal function and regional cerebral metabolism via dopamine D1
receptors (Trugman & James, 1993). SKF38393 has been shown to increase prolactin
anywhere from 3- to 40-fold in several species including humans. Its effect on prolactin
levels is rapid, peaking about 15–20 min after parenteral administration in the rat or sheep
(Cocchi et al., 1987; Tanimoto, Tamminga & Chase, 1987; Curlewis, Clarke & McNeilly,
1993), and prolactin levels return to baseline in about an hour. When given orally, the
delay is 60–150 min, returning to baseline within two to three hours (in humans; Fabbrini
et al., 1988). Some, but not all, studies report dose–response characteristics with regard
to prolactin secretion (Saller & Salama, 1986; Cocchi et al., 1987; Tanimoto, Tamminga &
Chase, 1987; Fabbrini et al., 1988; Curlewis, Clarke &McNeilly, 1993; Durham et al., 1998).
Here we report preliminary data from male baboons on the timing and magnitude
of prolactin response to anesthesia alone (N = 6), to SKF82958 (N = 1), to SKF38393
(N = 5), and to pramipexole (N = 1). Then we compare the prolactin and regional BOLD
(blood oxygen level dependent) fMRI responses to SKF38393 (N = 5).
MATERIALS & METHODS
Subjects
The study was approved by the Washington University Animal Studies Committee
(protocol # 20090112). We studied six healthy male olive baboons (Papio anubis). This
species was chosen with a goal of later translation to human studies; specifically, baboon
anatomy and neuroendocrine responses are similar to humans’, and their brain volume
is big enough to allow neuroimaging methods borrowed from human fMRI (Black et al.,
2009). Three were fully adult (age 6.8–14 years) and three were juveniles (age 4 years). In
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captive male baboons, puberty occurs at about 3.5 years of age (VandeBerg, 2009, p. xxi),
and the testes had descended in all subjects before these studies began.
Overall approach
We report results from three types of studies: time-course studies with anesthesia alone,
time-course studies with a dopamine agonist, and single-dose dopamine agonist studies.
To minimize drug sensitization and blood loss, no two studies in a given animal occurred
less than two weeks apart.
Time course studies
Anesthesia alone
First we charted the effects of ketamine and isoflurane on prolactin secretion over time
without administering a dopamine agonist, since both these anesthetic agents increase
plasma prolactin levels (Wickings & Nieschlag, 1980; Puri, Puri & Anand Kumar, 1981;
Crozier et al., 1994; Hergovich et al., 2001; Rizvi et al., 2001). We took a blood sample
as soon as possible after giving ketamine with the expectation that circulating prolactin
concentrations would not change for >20 min after i.m. ketamine (Rizvi et al., 2001).
The goal was to determine when the effects of ketamine and/or isoflurane on prolactin
release would reach an approximate steady state. Blood samples were taken in 4- to 20-min
intervals for up to 5 h.
With dopamine agonist
Time course studies were also done for the dopamine agonists to provide initial
information on whether the agonist produced a detectable effect on prolactin release in
this model and to determine a reasonable sampling time for the later single-dose studies.
The dopamine agonist was given two to three hours after ketamine, because although
prolactin concentration was still elevated at these times as a consequence of the anesthetics,
it was significantly reduced from its peak at around 60 min and was starting to level off
(see Results: anesthesia alone studies). Blood samples were taken at various intervals
before the agonists and at 4- to 20-min intervals afterward for a total of up to seven hours.
These studies involved either one dose of the dopamine agonist or three increasing doses,
each separated by one hour. The drug was infused i.v. over a five-minute period with a
syringe pump (Harvard Model 44). Drug infusion time was reckoned from the end of the
five-minute infusion period. Doses for SKF38393 ranged from 0.2 to 5.0 mg/kg, SKF82958
was given at 0.1 mg/kg, and pramipexole was given at 0.2 mg/kg.
Single-dose dopamine agonist studies
In these studies, a 40-min BOLD fMRI scan began at least 2 h after i.m. ketamine and
glycopyrrolate. Sedation from i.m. ketamine is long gone by this time, and a prolactin
increase after ketamine in rhesus monkeys had returned to baseline by 60 min (Quadri,
Pierson & Spies, 1978). A syringe pump delivered the dopamine agonist i.v. to anesthetized
subjects at a constant rate beginning at 15 min and ending at 20 min into the scan.
Five animals received varying doses of SKF38393, each dose on a different day. The
order of doses was random in each subject. The doses used were 0, 0.0928, 0.2, 0.431,
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0.928, 2.0, 4.31, and 9.28 mg/kg; not all subjects received all doses. A sixth animal received
pramipexole at doses of 0, 0.00928, 0.0431, 0.0928 and 0.2 mg/kg.
In these single-dose studies, blood samples for prolactin levels were taken just before
dopamine agonist administration and again 20–30 min after drug infusion ended (for
pramipexole, 60 min after infusion). The sampling time for each animal was based on the
results of the time course studies.
Anesthesia
Animals were fasted overnight before anesthesia. After ketamine 6–12 mg/kg i.m. and
glycopyrrolate (0.013–0.017 mg/kg i.m., to reduce secretions), orotracheal intubation was
performed via direct laryngeal visualization. Anesthesia was maintained with isoflurane
and oxygen beginning 10–30 min after ketamine. An i.v. catheter was placed in one or both
legs for drug delivery and withdrawing blood samples. Isoflurane delivery rate was adjusted
to maintain the concentration of isoflurane in expired air at the lowest level that would
reliably maintain sedation during study sessions. This concentration was measured by a
Surgivet V9400 monitor (Smiths Medical, Norwell, MA), and the optimal concentration
ranged from 0.95% to 1.45% across animals.
Drug preparation
SKF82958 (catalog # C130, Sigma-Aldrich, St Louis, MO) and SKF38393 (catalog #
D047, Sigma-Aldrich, St Louis, MO) were mixed fresh the day of the study, the pH
was adjusted with NaOH, then the solution was filter sterilized (0.22 µm) and stored
on ice in a light-tight container until use. SKF82958 was prepared with sterile 0.9%
saline at 1.0 mg/ml and the pH adjusted to 6.0–6.5. SKF38393 was prepared with sterile
water from 1.0 to 7.3 mg/ml and the pH adjusted to 5.5–6.0. Pramipexole (a gift from
Boehringer-Ingelheim Pharmaceuticals, Inc., Ridgefield, CT) was mixed with sterile saline
at 1 mg/ml and filter sterilized before use. Some pramipexole solution was kept in aliquots
at−80◦C for later use.
Plasma prolactin analysis
Prolactin concentration in plasma or serum was measured via radioimmunoassay
(University of Wisconsin National Primate Research Center, Madison, Wisconsin). The
inter-assay coefficient of variation was 7.89%, and the intra-assay coefficient of variation
was 4.09%.
MRI sequences and initial processing
All imaging was done on a Siemens Trio 3T scanner (Erlanger, Germany) with boosted
gradient coils. To facilitate image registration, an MP-RAGE sequence was used to acquire a
T1-weighted structural image of the head, flip angle 7◦, echo time (TE) 3.51 ms, inversion
time 1000 ms, FOV 192× 192 mm, 192 slices, and repetition time (TR) 1900 ms; and a 3D
turbo spin echo sequence was used to acquire a T2-weighted structural image, flip angle
120◦, TE 604 ms, field of view 256× 256 mm, 192 slices, and TR 3200 ms. Voxel size was
approximately (0.8 mm)3 for both structural images.
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Functional images were acquired using a blood oxygenation level-dependent (BOLD)
contrast-sensitive echo-planar sequence with flip angle 90◦, TE 30 ms, field of view
384× 384 mm, 32 slices, voxel size (2.5 mm)3, and TR 2160 ms, with interleaved slice
acquisition. Over a period of 40 min, 1111 volumes (frames) were acquired; the first 4
frames were discarded to ensure steady-state magnetization.
Functional images from each subject were preprocessed to reduce artifacts, including
correction for intensity differences due to interleaved acquisition, interpolation for slice
time correction, correction for head movement, and alignment to atlas space (Black et al.,
2001). Image intensity was not adjusted on a frame-by-frame basis, but the entire 40-min
acquisition was scaled linearly to a mean (across frames) whole-brain modal value of 1000.
Volumes of interest
Volumes of interest (VOIs) were defined by hand on each animal’s MP-RAGE (structural
image) for the following regions of brain: hypothalamus, pituitary, striatum, and
midbrain. The hypothalamus and pituitary were chosen because of the potential relevance
to prolactin release, and the striatum and midbrain to provide comparisons to prior blood
flow, metabolic, and BOLD pharmacological activation studies of dopamine agonists. The
regions were drawn with reference to Davis & Huffman (1968) by one author (BM) with
over 20 years’ experience in neuroanatomy (including delineating subnuclei in rodent
thalamus and tract tracing over the entire length of the primate brain). All regions were
drawn before any regional time-signal curves were examined. The VOIs were transferred to
the MRI by a validated cross-modality image registration method (Black et al., 2001).
Determination of ED50
The mean prolactin plasma concentration response to each dose of SKF38393 in the
single-dose studies was plotted against the logarithm of the dose. A sigmoid Emax model
(Holford & Sheiner, 1982) was fit to the data using a Markov chain Monte Carlo (McMC)
method (Bretthorst, 1988; Bretthorst & Marutyan, 2012). To improve sampling across the
logarithmic abscissa, a variable Q = log10(ED50) was defined and the McMC method was
used to estimate parameters in the equation
E(D)= E0+ Emax ·Dn/(Dn+ 10nQ),
where D= dose of SKF38393 in mg/kg, E0= response at baseline (D= 0), E(D)= response
(effect) at dose D, and n is the Hill coefficient. The response at each dose was defined as
post-drug minus pre-drug prolactin concentration on that same day (hence the nonzero
baseline response E0).
Separate dose–response curves and ED50 estimates were derived from mean BOLD
(fMRI) responses to SKF38393 and pramipexole in each VOI. The BOLD response at a
given dose was defined as the area under the BOLD signal curve (AUC) from 15 to 30 min
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Table 1 Baseline prolactin plasma concentration, and peak increase in prolactin with anesthesia
alone, by age.








R 4.08 2.62± 0.35 354%
T 4.25 3.04± 0.41 334%
B 4.33 2.64± 0.34 236%
E 6.75 4.05± 0.94 473%
S 6.92 3.50± 0.96 1198%
D 14.08 23.5± 6.02 410%
where time t is in minutes, BOLD(t) is the BOLD signal at each time point, and y =mt+ b
is the least-squares line fit to the first 15 min of BOLD signal data.
RESULTS
Baseline prolactin levels
Baseline prolactin levels were measured from the blood sample taken as soon as possible
after the subject was given ketamine. The delay between ketamine administration and the
first blood sample ranged from 6 to 24 min. These data showed no clear change in prolactin
levels during this time period. For example, one subject’s first sample was taken as soon
as eight minutes or as late as 24 min after ketamine (a total of 11 baseline samples were
examined for this subject). Prolactin levels were similar across these time points (data not
shown). The other subjects showed a similar pattern. Thus, changes in plasma prolactin
levels due to anesthetics appear to occur only after this time period.
Baseline levels of plasma prolactin were positively correlated with age (r = 0.96,
p < 0.01; Table 1). The oldest animal, at 14 years of age, had five-fold higher baseline
levels of prolactin than any of the other subjects, but the correlation with age remained
significant even excluding this subject. The three juveniles had the lowest baseline
measurements.
Effect of anesthesia alone on prolactin release
Anesthesia increased prolactin in all 6 animals (p = .03, 2-tailed binomial distribution),
with a peak concentration from 2.4-fold to 12-fold higher than at baseline (p< .07, 2-tailed
paired t test). The three juveniles had the lowest increase (Table 1).
Prolactin levels peaked between 50 and 90 min after ketamine. Prolactin levels declined
partially and leveled off somewhat around 100–120 min (Fig. 1). They continued to decline
but remained well above baseline levels for 3–5 h (last measurement, median 208 min) in
all animals (p = .03, 2-tailed binomial distribution; p < .07, 2-tailed paired t test). Some,
but not all, of the time course profiles appeared to show a small, secondary increase in
prolactin after 100 min. A similar post-decline surge has been recorded in other studies
with ketamine (Rizvi et al., 2001) and isoflurane (Reber et al., 1998).
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Figure 1 Plasma prolactin levels over time with anesthesia alone. Two time course studies of the effect
of anesthesia alone on prolactin plasma concentrations in two adults. The green line shows the period of
isoflurane inhalation. The orange arrow marks when the ketamine was given.
Prolactin release with anesthesia was greater in the adults than in the juveniles (Fig. 2;
p= 0.045).
Time course studies with dopamine agonists
Subsequent experiments attempted to detect an effect from the experimental drug on
prolactin release, and to define an appropriate time for sampling. SKF82958 at 0.1 mg/kg
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Figure 2 Age-related differences in prolactin secretionwith anesthesia. We performed an ANOVA with
age group as a between-subject factor and time (in 20-min bins) as a repeated measure. Every animal
had data out to at least the 121–140 min bin. Three missing values were imputed by averaging the
previous and following levels in that animal (these two values differed by only 24%, 13%, and 0%),
and in one animal the first sample was at 21′ and was treated as if it had been drawn at 20′. There was a
significant difference between juveniles and adults in the [PRL] response to anesthesia (age group× time
interaction F6,24 = 7.350, p= .045∗; main effect of age group F1,4 = 4.103, p= .113; main effect of time
F6,24 = 12.799, p= .018∗). ∗ = Greenhouse-Geisser correction for nonsphericity.
produced no apparent change in prolactin levels (N = 3), which continued to decline over
time in a pattern that was indistinguishable from the anesthesia-only condition (Fig. 3).
By contrast, the partial agonist SKF38393 appeared to produce a substantial increase in
prolactin (Fig. 4), including in the same adult whose non-response to SKF82958 appears
in Fig. 3. Prolactin levels increased as soon as five minutes after the drug infusion, peaked
within 20–30 min, then declined more gradually. The peak time was unique for each
animal but was 20–30 min after drug; this time determined when that animal’s blood
sample was to be taken after drug infusion during the single dose studies.
Prolactin declined shortly after pramipexole administration in the single subject tested,
with a substantial decline by 60 min and reaching a nadir about three hours later (Fig. 5).
Note that the prolactin concentrations dropped to well below baseline level.
Single-dose studies
SKF38393 and prolactin
The single dose studies showed a dose-related effect of SKF38393 on prolactin (Fig. 6). Two
adults (S, E) showed the most consistent and largest increases in prolactin, resulting in over
a 5-fold increase with the larger doses compared to pre-drug levels. One adult (D) and the
two juveniles had more modest and inconsistent increases, not exceeding a 2-fold increase
over pre-drug levels.
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Figure 3 SKF82958 effects on plasma prolactin. Data from one of the adult animals. A single dose of
0.1 mg/kg was given at 125 min after ketamine (blue line).
The [PRL] increase with drug was not monotonic. Of course, this comparison involves
results obtained on different days, and these results differed from the time course data, in
which a clear dose–response effect was visible when different doses were given within the
same session (Fig. 4). Figure 6 plots results as the difference in prolactin concentration
from the pre-drug levels, but similar variability was seen when the values are plotted as
percent of pre-drug levels or absolute concentrations of prolactin.
The group median dose–response curve for prolactin release following BOLD decreased
at the highest dose, so strictly the sigmoid Emax model may not apply. However,
recognizing this limitation, the model fit well to the remaining data points (0–4.31 mg/kg)
with an ED50 of 1.30 mg/kg (E0 =−3.65,Emax = 67.38,n= 1.03; Fig. 7).
SKF38393 and BOLD
There was a clear effect of SKF38393 on BOLD signal in midbrain at the higher doses
(Fig. 8; Fig. 9). BOLD signal in pituitary decreased with increasing dose, but it increased
in the other three regions (Fig. 10). The regional responses to the agonist, by dose, were
best fit to the sigmoid Emax model with ED50s of: hypothalamus, 2.57 mg/kg; pituitary,
3.85 mg/kg; midbrain, 5.59 mg/kg; and striatum, 8.06 mg/kg.
Pramipexole
The one animal given pramipexole (subject T, juvenile) showed a decrease in prolactin
concentration with the agonist at all doses tested (Table 2). The BOLD responses from this
animal are also given in Table 2.
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Figure 4 Time course of SKF38393 effects on plasma prolactin. (A) Plasma prolactin concentration
over time in an animal given a single dose of 2.0 mg/kg of SKF38393 125 min after ketamine. (B) Plasma
prolactin concentration over time in another animal given successive doses of 1.0, 2.0 and 5.0 mg/kg
of SKF38393 at 130, 197 and 264 min after ketamine. Vertical blue lines show the timing of drug
administration.
DISCUSSION
Anesthetic effects on prolactin
Our results with the anesthetics ketamine and isoflurane are very similar to those of
previous studies, showing an initial rise in prolactin levels followed by a gradual decline
(Reber et al., 1998; Puri, Puri & Anand Kumar, 1981; Rizvi et al., 2001; Hergovich et al.,
2001). Prior studies suggest that isoflurane may produce a larger prolactin response than
ketamine, though the data are from different species and sex. Isoflurane in human females
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Figure 5 Time course of pramipexole effects on plasma prolactin. A single dose of 0.2 mg/kg of
pramipexole (marked by the blue line) was given 180 min after ketamine.














0 −0.62a b b b b
0.00928 −2.73 130.5 15.9 115.1 140.2
0.04310 −8.10 54.0 −92.4 −22.6 60.6
0.09280 −3.53 47.3 −80.2 121.2 73.3
0.20000 −6.04 187.0 −92.7 −85.2 54.2
Notes.
a The prolactin response after the saline control is nonzero because it is defined as post-minus pre-drug, and prolactin levels are gradually declining following their initial
post-ketamine peak (see Fig. 1).
b Not available (marked artifact in numerous frames during this run).
has shown a 9 to 12-fold increase in prolactin (Reber et al., 1998; Marana et al., 2003), while
ketamine produced a 2- to 4-fold increase in male macaques after a single injection (Puri,
Puri & Anand Kumar, 1981; Rizvi et al., 2001). A study in adult baboon females found
no significant difference in PRL release between constant-rate i.v. ketamine and inhaled
halothane, both beginning after i.m. ketamine (Walker, 1987).
However, we saw a substantial range in the magnitude of the increase in our baboons,
with the lowest being 2.4-fold and the highest 12-fold. Five of the six subjects had
an increase of prolactin from anesthetics alone that ranged from 2.4-fold to 4.7-fold
compared to baseline values, suggesting that isoflurane was not producing as dramatic
an effect in our male baboons as it does in human females. In this study, we cannot reliably
separate the effects of the two anesthetics, but since ketamine’s anesthetic effects are largely
gone an hour after i.m. administration (discussed in Black, Gado & Perlmutter, 1997), the
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Figure 6 Dose-response curve for effect of SKF38393 on prolactin. Prolactin plasma concentration
after SKF38393 is plotted as the difference from each day’s pre-drug concentration. The inset shows a
close-up of the data from the two juveniles. Adults and juveniles differed in their responses (repeated
measures ANOVA, main effect of age group F1,3 = 18.068, p = .024; dose × age group interaction
F7,21= 4.780, p= .077∗; main effect of dose F7,21= 5.154, p= .068∗. ∗=Greenhouse-Geisser correction
for nonsphericity.
prolactin effects after 2–5 h likely are primarily attributable to isoflurane. However, even
this conclusion must be tempered by the caveat that drug effects on prolactin release are
somewhat delayed.
The blood samples taken as soon as practical after ketamine administration suggested
that prolactin levels did not begin to increase significantly until>20 min after ketamine,
though we necessarily lacked pre-ketamine data for comparison.
Dopamine agonist effects on prolactin
Our time course results with SKF38393 are similar to those previously published, with a
rapid increase in prolactin levels after drug administration (Tanimoto, Tamminga & Chase,
1987). In some instances we observed an increase in as little as five minutes after drug
infusion. Prolactin levels peaked by 20 to 30 min, followed by a gradual decline (Tanimoto,
Tamminga&Chase, 1987; Curlewis, Clarke &McNeilly, 1993; Cocchi et al., 1987).
Prolactin responses generally increased with higher doses of SKF38393, but in 3
animals the greatest response occurred at 2 or 4.31 mg/kg rather than at the highest dose,
9.28 mg/kg. This may simply be due to variability in the single-dose data as discussed
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Figure 7 ED50 for the mean prolactin response to SKF38393. The mean plasma [PRL] response to
SKF38393 in the single-dose studies was plotted against log(dose). The response at each dose was defined
as post-drug minus pre-drug [PRL] (hence the nonzero “response” in the absence of drug). A sigmoid
Emax model was fit to the data from 0 to 4.31 mg/kg as described in Materials & Methods under
“Determination of ED50”.
below. Alternatively, the physiological response of prolactin release may have an inverted U
shape. Resolving this question would require higher doses of drug and more subjects. We
ignored the data from the highest point in order to estimate an ED50 for prolactin response,
but we recognize the limitations in this approach.
The only previous data we found for prolactin response to the D1 agonist SKF82958
was from an in vitro study (Burris, Stringer & Freeman, 1991). Based on its action on D1
receptors and previous data from SKF38393, we predicted that SKF82958 would stimulate
prolactin release. At the dose used in the present study, SKF82958 produces changes in
regional cerebral blood flow (Black et al., 2000), but there was no clear evidence of a
change in prolactin release after this dose. One speculative explanation might be that
D1 full agonists do not affect prolactin release, while the partial agonist SKF38393 increases
prolactin release by its relative antagonism in the setting of intrinsic dopamine release.
The results from our pramipexole data are similar to those reported for human studies.
We see a dose-dependent reduction in prolactin levels (Schilling, Adamus & Palluk, 1992)
lasting for four hours or more after a single dose, with the lowest values seen several hours
after administration (Schilling, Adamus & Palluk, 1992; Porta et al., 2009; Hood et al., 2010).
Variability in the single-dose studies of prolactin response to
SKF38393
Our time-course studies suggested a clear dose–response effect from SKF38393 on plasma
prolactin levels (Fig. 4B), in that more drug produced more prolactin. Most other studies
report a similar effect (Tanimoto, Tamminga & Chase, 1987; Fabbrini et al., 1988; Curlewis,
Clarke & McNeilly, 1993; Cocchi et al., 1987; Saller & Salama, 1986; Durham et al., 1998).
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Figure 8 SKF38393 2 mg/kg caused a clear BOLD signal response in midbrain. BOLD signal in the
midbrain VOI during a 40-min functional MRI scan, after subtracting the linear trend computed from
the first 15 min of data. Data plotted here are from each animal’s 2 mg/kg day from the SKF38393
single-dose studies (mean ± S.D., N = 5). SKF38393 2 mg/kg was given i.v. over the time interval
indicated (15–20 min). Markers filled with red indicate points that differ significantly from zero (p< 0.05,
2-tailed single-sample t test); the marker filled with white indicates p= 0.0002.
However, as noted above, this relationship was less pronounced in the single-dose studies,
and possible reasons for this include the following.
The single-dose studies were conducted on separate days, and the physiological response
could vary for that reason, even though they were expressed in relation to the pre-drug
levels. The pre-drug levels varied from one session to another by as much as four-fold for
a single animal. This variability was present despite our efforts to maintain the expired
isoflurane at a consistent level throughout the study. With the small number of subjects
studied, deviations from a monotonic increase may reflect merely noise in the data.
Another potential source of variability is that a single post-drug sample, even at
a consistent time, may not always catch the maximal effect of the drug on prolactin
concentration. Also, though we attempted to maintain a similar time schedule (a two
hour delay from the time we first gave ketamine to the start of the BOLD scan), that varied
somewhat due to factors not under our control. Thus, there are multiple factors that could
contribute to the variability we saw in the single-dose data.
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Figure 9 Time-BOLD curves for SKF38393 in midbrain, by dose. Mean BOLD signal over time in
the midbrain VOI for the five highest doses of SKF38393 (N = 5). Each signal curve was detrended as
described in the previous figure legend. The drug was given i.v. between the 15 and 20 min marks.
Age effects on prolactin
Our data suggest that baboons may have age-related differences in basal plasma prolactin
levels. Our sample size is too small to reach a firm conclusion in this respect. However,
recently presented data from a large group of male P. anubis baboons showed that
serum prolactin does increase with age, peaking at around 13 years; fully adult males
have significantly higher serum prolactin concentrations than four-year-old males
(Phillips-Conroy et al., 2013). A report by Kondo et al. (2000) showed that prolactin levels
increase about 3-fold (on average) with age in male chimpanzees. However, this report
does not specify how long the blood sample was taken after administering ketamine and
the dopamine D2-like antagonist droperidol, and both of these agents increase prolactin
(Puri, Puri & Anand Kumar, 1981; Hayashi & Tadokoro, 1984; Schettini et al., 1989; Rizvi
et al., 2001; Hergovich et al., 2001). For comparison, human males have no significant
differences in prolactin levels from prepubescence to adulthood (Guyda & Friesen, 1973;
Aubert, Grumbach & Kaplan, 1974; Lee, Jaffe & Midgley, 1974; Ehara, Yen & Siler, 1975;
Finkelstein et al., 1978).
The fully adult animals also showed a greater prolactin response to the anesthetics and
to SKF38393 (Table 1, Figs. 2 and 6).
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Figure 10 Dose-response curves for the effect of SKF38393 on BOLD signal. The AUC at each dose of
SKF38393 is plotted (mean, N = 5) for midbrain, hypothalamus, pituitary, and striatum. AUC is defined
in the last paragraph of Methods.
BOLD responses to SKF38393
Noting the caveats above, the estimated prolactin ED50 for SKF38393 was 1.30 mg/kg. It
seems relevant that the VOI with the closest BOLD ED50 value to this was hypothalamus,
with an ED50 of 2.57 mg/kg.
CONCLUSIONS
In the baboon, the D1 agonist SKF38393 increased plasma prolactin levels, and caused
dose-related changes in BOLD signal in several brain regions, hypothalamus, pituitary
and midbrain being more sensitive than striatum. From limited data, the D2-like agonist
pramipexole produced a decline in prolactin levels, and the D1 agonist SKF82958 did not
affect prolactin release.
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